299 related articles for article (PubMed ID: 24064822)
21. [Molecular targeting therapy for chronic myeloid leukemia].
Kimura S
Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
[No Abstract] [Full Text] [Related]
22. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
23. First-line therapy for chronic myeloid leukemia: Past, present, and future.
Pavlovsky C; Kantarjian H; Cortes JE
Am J Hematol; 2009 May; 84(5):287-93. PubMed ID: 19306355
[TBL] [Abstract][Full Text] [Related]
24. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Hantschel O; Rix U; Superti-Furga G
Leuk Lymphoma; 2008 Apr; 49(4):615-9. PubMed ID: 18398720
[TBL] [Abstract][Full Text] [Related]
25. [Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].
Gómez Casares MT; León LG
Med Clin (Barc); 2013 Aug; 141(3):111-3. PubMed ID: 23462544
[No Abstract] [Full Text] [Related]
26. Second-generation BCR-ABL kinase inhibitors in CML.
Akard LP
N Engl J Med; 2010 Oct; 363(17):1672-3; author reply 1673-5. PubMed ID: 20973144
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
29. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Jabbour E; Kantarjian HM; Jones D; Reddy N; O'Brien S; Garcia-Manero G; Burger J; Cortes J
Blood; 2008 Dec; 112(13):4839-42. PubMed ID: 18818391
[TBL] [Abstract][Full Text] [Related]
30. Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
Aoki J; Ohashi K; Kobayashi T; Kakihana K; Hirashima Y; Sakamaki H
Leuk Lymphoma; 2012 Jul; 53(7):1412-4. PubMed ID: 22168276
[No Abstract] [Full Text] [Related]
31. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
[No Abstract] [Full Text] [Related]
32. Even better kinase inhibitors for chronic myeloid leukemia.
Sawyers CL
N Engl J Med; 2010 Jun; 362(24):2314-5. PubMed ID: 20525994
[No Abstract] [Full Text] [Related]
33. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Cortes J; Mauro M; Steegmann JL; Saglio G; Malhotra R; Ukropec JA; Wallis NT
Am J Hematol; 2015 Apr; 90(4):E66-72. PubMed ID: 25580915
[TBL] [Abstract][Full Text] [Related]
34. [Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Burchert A; Neubauer A
Internist (Berl); 2011 Mar; 52(3):283-93; quiz 294-5. PubMed ID: 21253680
[TBL] [Abstract][Full Text] [Related]
35. [Chronic myeloid leukemia: up-to-date management].
Nakayama K; Inokuchi K
Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
[No Abstract] [Full Text] [Related]
36. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
[TBL] [Abstract][Full Text] [Related]
37. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Swords R; Alvarado Y; Cortes J; Giles FJ
Curr Hematol Malig Rep; 2007 May; 2(2):83-8. PubMed ID: 20425355
[TBL] [Abstract][Full Text] [Related]
38. Chronic myelogenous leukemia for primary care physicians.
Torgerson SR; Haddad RY; Atallah E
Dis Mon; 2012 Apr; 58(4):168-76. PubMed ID: 22449366
[No Abstract] [Full Text] [Related]
39. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Hjorth-Hansen H; Stenke L; Söderlund S; Dreimane A; Ehrencrona H; Gedde-Dahl T; Gjertsen BT; Höglund M; Koskenvesa P; Lotfi K; Majeed W; Markevärn B; Ohm L; Olsson-Strömberg U; Remes K; Suominen M; Simonsson B; Porkka K; Mustjoki S; Richter J;
Eur J Haematol; 2015 Mar; 94(3):243-50. PubMed ID: 25082346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]